METAMIDE 1. Product Name - Medsafe

1 Page 1 of 8 NEW ZEALAND DATA SHEETMETAMIDE1. Product NameMETAMIDE, 10 mg, Qualitative and Quantitative CompositionEach tablet contains 10 mgof metoclopramide (as hydrochloride) METAMIDE tablets contain lactoseFor the full list of excipients, see section Pharmaceutical FormTablets 10mg: White, biconvex tablets, 9/32 diameter imprinted M/10 on one Clinical Therapeutic indicationsAdults (20 years and over):Digestive DisordersMETAMIDE restores normal co-ordination and tone to the upper digestive tract and relieves symptoms of gastroduodenal dysfunction including: Dyspepsia Heartburn Flatulence Sickness Regurgitation of bile PainThese symptoms may be associated with such conditions as: Peptic ulcer Duodenitis Reflux oesophagitis Gastritis Hiatus hernia Cholelithiasis and post-cholecystectomy dyspepsiaNausea and vomitingMETAMIDE is indicated in the treatment of nausea and vomiting associated with.

2 Page 2 of 8 Gastrointestinal disorders Cyclical vomiting Intolerance to cytotoxic medicines Congestive heart failure Deep x-ray or cobalt therapy Post-anaesthetic vomitingMigraineMETAMIDE relieves symptoms of nausea and vomiting, and overcomes gastric stasis associated with attacks of migraine. This improvement in gastric emptying assists the absorption of concurrently administered oral antimigraine therapy ( paracetamol) which may otherwise be impaired in such conditions Post-operative gastric hypotonia Post-vagotomy syndromeMETAMIDE promotes normal gastric emptying and restores motility in vagotomised patients, and where postoperative symptoms suggest gastroduodenal procedures Radiology Duodenal intubationMETAMIDE speeds up the passage of a barium meal by decreasing gastric emptying time, co-ordinating peristalsis and dilating the duodenal bulb.

3 METAMIDE also facilitates duodenal intubation adults and children over 1 The use of METAMIDE in patients under 20 years should be restricted to the following and used only as second line therapy: Severe intractable vomiting of known cause Vomiting associated with radiotherapy and intolerance to cytotoxic medicines As an aid to gastrointestinal intubation As part of the premedication before surgical and method of administrationThis Product is not able to deliver all approved dose dosage recommendations given below should be strictly adhered to if side effects of the dystonic type are to be avoided.

4 It should be noted that total daily dosage of METAMIDE , especially for children and young adults, should not normally exceed mg/kg body weight or 30mg daily. In patients with clinically significant degrees of renal or hepatic impairment, therapy should be at reduced dosage. metoclopramide is metabolised in the liver and the predominant route of elimination of metoclopramide and its metabolites is via the kidney. Maximum recommended treatment duration is 5 days in all age IndicationsAdults (20 years and older)Maximum 10mg three times patients less than 60kg, see Table 3 of 8 Special populationsElderlypatients (as for adults)

5 To avoid adverse reactions,adhere strictly to dosage recommendations and where prolonged therapy is considered necessary, patients should be regularly adults and childrenMETAMIDE should only be used after careful examination to avoid masking an underlying disorder cerebral irritation. In the treatment of this group attention should be given primarily to body weight and treatment should begin at the lower dosage where stated. METAMIDE should be used as second line therapy in these should not be used in children under the age of 1 Young Adults15 - 19 years60kg & over10 mg three times daily30kg - 59kg5 mg three times dailyChildren9 - 14 years30kg & over5 mg three times daily5 - 9 years20kg - mg three times daily3 - 5 years15 - 19kg2 mg two to three times daily1 - 3 years10 - 14kg1 mg two to three timesdailyDiagnostic indicationsA single dose of METAMIDE may be given 5-10 minutes before the examination.

6 Subject to body weight considerations (see above) the following dosages are recommended:Table to the active substanceor to any of the excipients listed in section should not be used whenever stimulation of gastrointestinal motility might be dangerous, the presence of gastrointestinal haemorrhage, mechanical obstruction, or 20 years and over10 20 mgYoung Adults15 - 19 years10 mgChildren9 - 14 years5 - 9 years3 - 5 years1 - 3 years5 mg mg 2 mg1 mgPage 4 of 8 metoclopramide is contraindicated in patients with phaeochromocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumour.

7 Such hypertensive crises may be controlled by is contraindicated in patients with known hypersensitivity or intolerance to the is contraindicated in children under 1 year of age. metoclopramide is contraindicated in patients with should not be used in patients with epilepsy since it may increase the frequency and severity of should not be administered to patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of extrapyramidal reactions may be warnings and precautions for useDystonic reactionsOccurs in approximately 1% of patients given metoclopramide .

8 These occur more frequently in children and young adults and may occur after a single tardive dyskinesiaTardive dyskinesia may appear in some patients on long- term therapy or may appear after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high dose therapy, especially females. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterised by rhythmical involuntary movement of the tongue, face, mouth or jaw ( protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements).

9 Sometimes these may be accompanied by involuntary movement of extremities. There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. Although the risk of tardive dyskinesia with metoclopramide has not been extensively studied, one published study reported a tardive dyskinesia prevalence of 20% among patients treated for at least 3 months. Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the total cumulative therapy should routinely be discontinued in patients who develop signs or symptoms of tardive dyskinesia.

10 It has been suggested that fine vermicular movements of thetongue may be an early sign of the syndrome, and, if the medication is stopped at that time, the syndrome may not develop. Tardive dyskinesia may remit partially or completely within several weeks to months after metoclopramide is withdrawn. metoclopramide itself, however, may suppress (or partially suppress) the signs of tardive dyskinesia thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of the syndrome is unknown.